✦ LIBER ✦

Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies

✍ Scribed by Frank R. Brennan; Gordon Dougan

Book ID: 116957781
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 143 KB
Volume: 23
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2004.11.072

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved Clinical Evaluation of Prospect

Improved Clinical Evaluation of Prospective Vaccines and New Therapies against AIDS

✍ VADIM I. KVITASH; ROBERT M. SCHMIDT 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

A controlled clinical trial comparing th

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

✍ Juan Dupont; Javier Altclas; Alejandro Lepetic; Mónica Lombardo; Vicente Vázquez 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Evaluation of a new Rift Valley fever va

Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials

✍ Gilcin F. Meadors III; Paul H. Gibbs; C.J. Peters 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 588 KB

Preclinical and clinical evaluation of a

Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine

✍ Reinhard Glück 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 83 KB

Development and preclinical safety evalu

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

✍ Anders Fomsgaard; Ingrid Karlsson; Gregers Gram; Christian Schou; Sheila Tang; P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 337 KB

Safety evaluation of a new allergy vacci

Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy

✍ Paul Baldrick; Derek Richardson; Alan W. Wheeler; Stefan R. Woroniecki 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract A novel allergy vaccine (Pollinex^®^ Quattro) has been developed for the prevention or relief of allergic symptoms caused by a variety of pollens. Within this range, the grass pollen allergy vaccine contains extracts of 12 grass pollens and rye cereal (all chemically modiﬁed by glutaral